A Phase 3 interventional study of Argon laser trabeculoplasty and Selective laser trabeculoplasty in Glaucoma, sponsored by London Health Sciences Centre Research Institute and Lawson Research Institute of St. Joseph's. Status unknown at 7 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-03-06.
Sponsored by London Health Sciences Centre Research Institute and Lawson Research Institute of St. Joseph's · Phase 3, Interventional, and Treatment
Lasers are important therapy in glaucoma. They are a pivotal point in treatment between medical and surgical care. Over the last 10 years a new laser has emerged as the usual laser treatment: Selective laser trabeculoplasty (SLT). SLT works as well as the older laser used: argon laser trabeculoplasty (ALT). However SLT has many theoretical benefits over ALT including causing less damage to the tissue it affects. One of the potential patient centered benefits of this laser is that it may be repeatable. It is even possible that the old laser ALT may be useable after an SLT treatment. This study aims to uncover whether repeat laser is possible after SLT and if so which laser is more effective (ALT vs SLT). The potential of repeating laser therapies may delay surgical treatment and its complications. Also understanding which laser to use will help eye doctors know how to treat their patients at this point of the disease.
1,818 studies on the registry are indexed under Glaucoma; 231 are open to participants now.
This study's enrollment of 139 is above the median of 65 across 1,272 interventional studies indexed under Glaucoma.
Browse Glaucoma studies →London Health Sciences Centre Research Institute and Lawson Research Institute of St. Joseph's is the lead sponsor of 352 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Up to the year 2005, the vast majority of ophthalmologists used Argon laser trabeculoplasty (ALT) as the mode of laser therapy. ALT is effective but its most significant problem is that its effectiveness decreases with re-treatment since the tissue it targets (the trabecular meshwork) is changed by the laser rendering repeat treatments less effective.
Procedure: Argon laser trabeculoplasty · Procedure: Selective laser trabeculoplasty
Post 2005, a newer mode of laser therapy, selective laser trabeculoplasty (SLT) has emerged as the standard of care laser. There are many potential advantages to SLT but to date these advantages are only theoretical. The most important potential clinical advantage of SLT is that it causes less damage to the tissue it targets.
Procedure: Argon laser trabeculoplasty · Procedure: Selective laser trabeculoplasty
With Argon laser trabeculoplasty (ALT), thermal energy is used directed towards the Trabecular Meshwork (the site of aqueous drainage from the eye),which causes focal scarring of trabecular meshwork, thus enable fluid drainage more effectively. However, this procedure may not be repeatable since it causes too much damage to the trabecular meshwork.
Selective laser trabeculoplasty is a relatively newer technology that uses a Nd:YAG laser to target specific cells within the trabecular meshwork. SLT does not cause coagulative damage to the trabecular meshwork, and thus has the advantage of being repeatable.
Intraocular Pressure
IOP difference between baseline and 12 month post-laser.
Time frame: 12 months post operatively
To compare the IOP lowering effect between the groups at other postoperative visits
IOP difference between baseline, 1hr, 1 wk, and 1, 3, 6 and 12 mon post-laser.
Time frame: 12 months
To compare the visual acuity between the groups at all visits.
VA difference between baseline, 1hr, 1 wk, and 1, 3, 6 and 12 mon post-laser.
Time frame: 12 months
To compare the trabecular meshwork pigmentation between the groups at all visits.
Time frame: 12 months
To compare any adverse events between the two groups at all visits.
Time frame: 12 months
SLT repeatability of long term follow up in glaucoma patients
The follow up time has been extended two more years. Patients will be followed up Q6 months.
Time frame: 36 months after initial enrollment of the primary study
This study is status unknown, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
London Health Sciences Centre Research Institute and Lawson Research Institute of St. Joseph's